Serum Institute Gets DCGI Nod For Phase 2/3 Clinical Trials Of Oxford COVID-19 Vaccine
New Delhi: Drug regulator the Drugs Controller General of India (DCGI) has given n od to the Serum Institute of India (SII) for conducting phase 2 and 3 human clinical…
Share